Boehringer Ingelheim Venture Fund Overview

  • Investor Type
  • Venture Capital
  • Status
  • Active
  • Professionals
  • 13
Professionals
  • Investments
  • 83
  • Portfolio
  • 38
  • Exits
  • 15
Exits

Boehringer Ingelheim Venture Fund General Information

Description

Established in 2010, Boehringer Ingelheim Venture Fund is a venture capital arm of Boehringer Ingelheim headquartered in Ingelheim am Rhein, Germany. The firm prefers to invest in companies operating in the healthcare sector.

Contact Information

Year Founded
2010
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
Corporate Venture Capital
Primary Office
  • Binger Straße 173
  • 55216 Ingelheim am Rhein
  • Germany
+49 06132 00000000

Boehringer Ingelheim Venture Fund Investments (83)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Topas Therapeutics 29-Jul-2021 Later Stage VC 000.00 Drug Discovery Clinical Trials - Phase 1 000000000 00000 00.0
0000000000 14-Jul-2021 00000 00000 000.00 Other Healthcare Technology Systems Clinical Trials - General 000000 00000
000000 23-Jun-2021 00000 00000 000.00 Outcome Management (Healthcare) Generating Revenue/Not Profitable 0000 00000
00000000 30-Apr-2021 00000 00000 0000 Biotechnology Pre-Clinical Trials 00000 00000 00.0
00000 000000000000 20-Apr-2021 00000 00000 000.00 Drug Discovery Clinical Trials - General 00000 00000000000 00.0
0000.000 31-Mar-2021 00000 00000 Managed Care Stealth
000000 00000000000 10-Mar-2021 00000 00000 0000 Biotechnology Pre-Clinical Trials 0000 00000 00.0
0000000 00000000 10-Mar-2021 0000 00000 0000 Pharmaceuticals Startup
Perfood 30-Nov-2020 Early Stage VC 00.000 Other Healthcare Technology Systems Generating Revenue 000000 00000
ImCheck Therapeutics 15-Sep-2020 Later Stage VC 0000 Drug Discovery Clinical Trials - Phase 1 000000 000000000 00.0
You’re viewing 10 of 83 investments. Get the full list »
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Boehringer Ingelheim Venture Fund Exits (15)

Company Name Exit Date Exit Type Exit Size
Abexxa Biologics 21-Sep-2021 Merger/Acquisition
0000 0000000000000 04-Jan-2021 000000000000000000 0000
000 000000000000 01-Dec-2020 000000000000000000 00.00
0000000 20-Apr-2020 000000000000000000
0000 000000000000 15-Jul-2019 000000000000000000 00000
00000 000000000000 01-Jun-2019 000000000000000000 00000
0000000 000000 18-Apr-2019 000 0000
000 000000000000 29-Mar-2019 000000000000000000
ViraTherapeutics 13-Sep-2018 Merger/Acquisition 00000
STAT-Dx 19-Apr-2018 Merger/Acquisition 00000
You’re viewing 10 of 15 exits. Get the full list »

Boehringer Ingelheim Venture Fund Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Boehringer Ingelheim Venture Fund Team (30)

Name Title Deals Funds Boards Office
Martin Heidecker Ph.D Managing Director 0 0 0 Cambridge, MA
Weiyi Zhang Ph.D Managing Director 0 0 0 Beijing, China
Frank Kalkbrenner Ph.D Global Head, Director & Investment Manager 00 0 00 Ingelheim am Rhein, Germany
Viktor Dzimiera Finance Director Ingelheim am Rhein, Germany
Markus Barner Executive Ingelheim am Rhein, Germany
You’re viewing 5 of 30 team members. Get the full list »

Boehringer Ingelheim Venture Fund Co-Investors (152)

Name With Exits Lead Partner Series Industry
High-Tech Gründerfonds 6 0 0 Series chart Industry bar
BioMedPartners 0 0 0 Series chart Industry bar
Life Sciences Partners 0 0 Series chart Industry bar
PMV 0 0 Series chart Industry bar
Pontifax Venture Capital 0 0 Series chart Industry bar
You’re viewing 5 of 152 co-investors. Get the full list »